T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.53B |
| 2 |
Amazon
AMZN
|
+$1.59B |
| 3 |
Waters Corp
WAT
|
+$1.55B |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$1.17B |
| 5 |
Ascendis Pharma A/S
ASND
|
+$1.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.71B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$1.54B |
| 3 |
NVIDIA
NVDA
|
+$1.34B |
| 4 |
Amphenol
APH
|
+$1.34B |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.05% |
| 2 | Healthcare | 20.39% |
| 3 | Consumer Discretionary | 14.54% |
| 4 | Industrials | 10.59% |
| 5 | Financials | 9.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
IonQ
IONQ
$16.6B
| $741K | ﹤0.01% |
25,678
| – | – |
|
627
Lam Research
LRCX
$390B
| $706K | ﹤0.01% |
+3,301
| New | +$738K |
|
628
Analog Devices
ADI
$190B
| $673K | ﹤0.01% |
2,113
+827
| +64% | +$263K |
|
629
Leidos
LDOS
$17.3B
| $568K | ﹤0.01% |
+3,648
| New | +$655K |
|
630
Mueller Industries
MLI
$15.2B
| $535K | ﹤0.01% |
9,646
+9,360
| +3,273% | +$561K |
|
631
Parker-Hannifin
PH
$135B
| $509K | ﹤0.01% |
568
-706
| -55% | -$668K |
|
632
IQVIA
IQV
$39.3B
| $506K | ﹤0.01% |
2,965
+387
| +15% | +$75.5K |
|
633
Newmont
NEM
$119B
| $506K | ﹤0.01% |
+4,672
| New | +$539K |
|
634
VeriSign
VRSN
$26.6B
| $458K | ﹤0.01% |
1,842
-692
| -27% | -$165K |
|
635
Hubbell
HUBB
$27.2B
| $436K | ﹤0.01% |
887
-781
| -47% | -$384K |
|
636
Cigna
CI
$74.6B
| $372K | ﹤0.01% |
1,393
-1,815
| -57% | -$502K |
|
637
Southern Copper
SCCO
$166B
| $342K | ﹤0.01% |
+2,002
| New | +$366K |
|
638
Humana
HUM
$46.2B
| $324K | ﹤0.01% |
1,866
+1,095
| +142% | +$224K |
|
639
Autodesk
ADSK
$52.6B
| $315K | ﹤0.01% |
1,313
-67,313
| -98% | -$16.9M |
|
640
Boston Scientific
BSX
$71.5B
| $298K | ﹤0.01% |
+4,745
| New | +$380K |
|
|
APLS
641
DELISTED
Apellis Pharmaceuticals
APLS
| $208K | ﹤0.01% |
5,162
+3,188
| +161% | +$68.7K |
|
642
DexCom
DXCM
$32B
| $207K | ﹤0.01% |
3,293
+606
| +23% | +$42.2K |
|
643
Regeneron Pharmaceuticals
REGN
$80.8B
| $207K | ﹤0.01% |
+267
| New | +$204K |
|
644
Asbury Automotive
ABG
$3.85B
| – | – |
-20
| Closed | -$5K |
|
|
ABVX
645
Abivax
ABVX
$11.4B
| – | – |
-452
| Closed | -$61K |
|
646
ACI Worldwide
ACIW
$5.42B
| – | – |
-43
| Closed | -$3K |
|
647
Aecom
ACM
$9.75B
| – | – |
-147
| Closed | -$15K |
|
648
Agree Realty
ADC
$9.41B
| – | – |
-347
| Closed | -$25K |
|
649
Archer Daniels Midland
ADM
$36.9B
| – | – |
-75
| Closed | -$5K |
|
650
Advantage Solutions
ADV
$361M
| – | – |
-118,005
| Closed | -$2.6M |
|
Similar funds
T. Rowe Price Investment Management's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Investment Management held 968 positions worth $145B, down 8.3% from $158B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
T. Rowe Price Investment Management withdrew a net $7.64B in Q1 2026, closing 325 positions and reducing 267 holdings. Its most notable exit was KKR & Co, an estimated $1.1B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Investment Management opened a new position in Netflix worth $731M.
- T. Rowe Price Investment Management's largest Q1 2026 buy was Netflix: 7,603,053 shares worth $731M.
- T. Rowe Price Investment Management added most to Meta Platforms (Facebook) in Q1 2026, an estimated $2.53B increase.
- T. Rowe Price Investment Management's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.71B.
- T. Rowe Price Investment Management fully exited KKR & Co in Q1 2026, selling an estimated $1.1B.
- T. Rowe Price Investment Management's ten largest holdings make up 23% of its $145B portfolio in Q1 2026.
- T. Rowe Price Investment Management opened 71 new positions and closed 325 in Q1 2026.
- T. Rowe Price Investment Management's portfolio value fell 8.3% quarter-over-quarter to $145B.
Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.